VU6012962 (VU-6012962) is a potent, orally bioavailable and CNS penetrant mGlu7 negative allosteric modulator with IC50 of 0.35 uM.

VCMMAE-(PEG)4-DBCO is made by MMAE conjugated to DBCO-(PEG)4-vc-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

Vaborbactam is a cyclic boronic acid pharmacophore β-lactamase inhibitor.

UK-371804 is a potent and selective uPA inhibitor with excellent enzyme potency (Ki 10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin).

UAMC00039 dihydrochloride is a potent inhibitor of dipeptidyl peptidase II (DPP-II) (IC50 = 0.48 nM).

U 19963 is a bioactive compound.

The intermediate of ARS-853.ARS-853 is a selective, covalent inhibitor of KRAS-G12C that inhibits mutant KRAS driven signaling by binding to the GDP bound oncoprotein and preventing activation.

The first small molecule ligand for the VEGF-A receptor neuropilin 1 (NRP1).

TGF-β receptor inhibitor

SU 4313 is a bioactive chemical.

SR-14150 is a potent NOP/μ-opioid partial agonist with Ki of 1.39 nM and 29.9 nM, respectively.

Spastazoline is a potent and selective spastin (a microtubule-severing AAA protein) inhibitor, with an IC50 of 99 nM for Human spastin. Spastazoline shows no effect on ATPase activity of a recombinant human VPS4.

SNG-1153 is a synthetic modulator of ER-α36

SGI-110 (S-110) is a stable and potent inhibitor for DNA methylation, inhibits DNMT1 when SGI-110 is activated by phosphorylation and incorporated into DNA.

SB218078 is an inhibitor of checkpoint kinase 1 (Chk1) that displays selectivity over other protein kinases (IC50 values are 15, 250 and 1000 nM for Chk1, cdc2 and PKC respectively).

Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy.

Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy.

Sapacitabine is an orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity.

PRT-060318 is a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.

PRL-8-53|cas 51352-88-6

Olutasidenib is a highly potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 that could be used in the treatment of acute myeloid leukemia.

Ochratoxin B(OTB) is a non-chlorinated analog of OTA that has cytotoxic effects on kidney and liver cells in vitro but only minor effects in vivo, due to its rapid metabolism and excretion.

Ochratoxin A demonstrates nephrotoxicity and teratogenesis in animals, and shows inhibition of bacterial, yeast, and liver FARSL (phenylalanyl-tRNA synthetases) competitive with phenylalanine.

NSC 31205 is a PIM2/1 inhibitor.

NSC 191412 is a bioactive compound.

Nifenalol is a beta-adrenoceptor antagonist.

Negative control for the Src kinase inhibitor PP2.

NCC007 is a novel CKIα and CKIδ dual inhibitor. NCC007 that showed stronger period effects (0.32 μM for 5 h period lengthening) in a cellbased circadian assay.

N-[2-(methylsulfanyl) phenyl]acetamide.

MT1 is a bivalent chemical probe of BET bromodomains.MT1 is an intramolecular bivalent BRD4 binder that is more than 100-fold more potent, in cellular assays, than the corresponding monovalent antagonist, JQ1.